Skip to main content
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Research Article

Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma

verfasst von: Sami K. Saarelainen, Synnöve Staff, Nina Peltonen, Terho Lehtimäki, Jorma Isola, Paula M. Kujala, Maarit H. Vuento, Johanna U. Mäenpää

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Preoperative evaluation of the risk for metastases in endometrial carcinoma is challenging. The growth of new vessels, angiogenesis, is important for tumor growth and purported to be involved in the metastatic process. The aim of this study was to evaluate the significance of preoperative serum levels and immunohistochemical expression of angiogenic markers in predicting a metastasized disease. Preoperative sera from 98 consecutive women presenting with endometrial carcinoma were collected. Serum concentrations of VEGF, sFLT1, and CD105 were assessed by enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry was used to assess the expression of CD105, VEGF, FLT1, and KDR. The results were correlated to the presence of metastases, presence of deep (≥50 %) myometrial invasion, and the histological grade of the tumor. Tumors with other than endometrioid histology were excluded. Of the 80 evaluable patients, 11 had a metastasized disease. The serum concentration of VEGF was higher in the group with metastases than in the group without metastases (median [range], 743 pg/mL [546–1,183 pg/mL] vs. 383 pg/mL [31–1,524 pg/mL], p < 0.001, respectively). In the multivariable analysis, the concentration of VEGF was the sole independent, albeit weak predictive factor for the presence of metastases (odds ratio, 1.004, 95 % confidence interval, 1.002–1.007; p = 0.001). The immunohistochemical expression of the markers was not associated with any of the clinicopathological features of the tumors. The results of the present study suggest that preoperative serum VEGF concentration correlates with the presence of metastases in endometrioid endometrial carcinoma.
Literatur
2.
Zurück zum Zitat Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer. 1987;60:2035–41.CrossRefPubMed Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer. 1987;60:2035–41.CrossRefPubMed
3.
Zurück zum Zitat Chan JK, Kapp DS, Cheung MK, et al. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol. 2008; 198:216.e1–216.e5. Chan JK, Kapp DS, Cheung MK, et al. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol. 2008; 198:216.e1–216.e5.
4.
Zurück zum Zitat Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18:269–73.CrossRefPubMed Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18:269–73.CrossRefPubMed
5.
Zurück zum Zitat Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527–43.CrossRefPubMed Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527–43.CrossRefPubMed
6.
Zurück zum Zitat Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010;13:43–58.CrossRefPubMed Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010;13:43–58.CrossRefPubMed
7.
Zurück zum Zitat Wu FT, Stefanini MO, Mac Gabhann F, et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14:528–52.PubMed Wu FT, Stefanini MO, Mac Gabhann F, et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14:528–52.PubMed
8.
Zurück zum Zitat Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling—in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.CrossRefPubMed Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling—in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.CrossRefPubMed
9.
Zurück zum Zitat Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–30.PubMed Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–30.PubMed
10.
Zurück zum Zitat Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931–7.CrossRefPubMed Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931–7.CrossRefPubMed
11.
Zurück zum Zitat Mutch DG. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol. 2009;115:325–8.CrossRef Mutch DG. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol. 2009;115:325–8.CrossRef
12.
Zurück zum Zitat Yokoyama Y, Sato S, Futagami M, et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol. 2000;77:413–8.CrossRefPubMed Yokoyama Y, Sato S, Futagami M, et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol. 2000;77:413–8.CrossRefPubMed
13.
Zurück zum Zitat Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13:7487–95.CrossRefPubMed Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13:7487–95.CrossRefPubMed
14.
Zurück zum Zitat Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic “vascular endothelial growth factor/flk-1(KDR) receptor” pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer. 2001;92:2569–77.CrossRefPubMed Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic “vascular endothelial growth factor/flk-1(KDR) receptor” pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer. 2001;92:2569–77.CrossRefPubMed
15.
Zurück zum Zitat Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol. 2001;80:181–8.CrossRefPubMed Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol. 2001;80:181–8.CrossRefPubMed
16.
Zurück zum Zitat Lee CN, Cheng WF, Chen CA, et al. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol. 2000;96:615–21.PubMed Lee CN, Cheng WF, Chen CA, et al. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol. 2000;96:615–21.PubMed
17.
Zurück zum Zitat Ozbudak IH, Karaveli S, Simsek T, et al. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol. 2008;108:603–8.CrossRefPubMed Ozbudak IH, Karaveli S, Simsek T, et al. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol. 2008;108:603–8.CrossRefPubMed
18.
Zurück zum Zitat Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003;9:1361–9.PubMed Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003;9:1361–9.PubMed
19.
Zurück zum Zitat Fine BA, Valente PT, Feinstein GI, et al. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol. 2000;76:33–9.CrossRefPubMed Fine BA, Valente PT, Feinstein GI, et al. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol. 2000;76:33–9.CrossRefPubMed
20.
Zurück zum Zitat Fujimoto J, Ichigo S, Hirose R, et al. Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett. 1998;134:15–22.CrossRefPubMed Fujimoto J, Ichigo S, Hirose R, et al. Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett. 1998;134:15–22.CrossRefPubMed
21.
Zurück zum Zitat Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol. 2005;26:81–7.CrossRefPubMed Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol. 2005;26:81–7.CrossRefPubMed
22.
Zurück zum Zitat Chen CA, Cheng WF, Lee CN, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol. 1999;74:235–40.CrossRefPubMed Chen CA, Cheng WF, Lee CN, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol. 1999;74:235–40.CrossRefPubMed
23.
Zurück zum Zitat Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385–92.CrossRefPubMedPubMedCentral Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385–92.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Bozas G, Terpos E, Gika D, et al. Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy. Int J Gynecol Cancer. 2010;20:248–54.CrossRefPubMed Bozas G, Terpos E, Gika D, et al. Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy. Int J Gynecol Cancer. 2010;20:248–54.CrossRefPubMed
25.
Zurück zum Zitat Gornall RJ, Anthony FW, Coombes EJ, et al. Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement. Int J Gynecol Cancer. 2001;11:164–6.CrossRefPubMed Gornall RJ, Anthony FW, Coombes EJ, et al. Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement. Int J Gynecol Cancer. 2001;11:164–6.CrossRefPubMed
26.
Zurück zum Zitat Bando H, Weich HA, Brokelmann M, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005;92:553–61.PubMedPubMedCentral Bando H, Weich HA, Brokelmann M, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005;92:553–61.PubMedPubMedCentral
27.
Zurück zum Zitat Chang YT, Chang MC, Wei SC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas. 2008;37:145–50.CrossRefPubMed Chang YT, Chang MC, Wei SC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas. 2008;37:145–50.CrossRefPubMed
28.
Zurück zum Zitat Aref S, El Sherbiny M, Goda T, et al. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 2005;10:131–4.CrossRefPubMed Aref S, El Sherbiny M, Goda T, et al. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 2005;10:131–4.CrossRefPubMed
29.
Zurück zum Zitat Saad RS, Jasnosz KM, Tung MY, et al. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol. 2003;22:248–53.CrossRefPubMed Saad RS, Jasnosz KM, Tung MY, et al. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol. 2003;22:248–53.CrossRefPubMed
30.
Zurück zum Zitat Salvesen HB, Gulluoglu MG, Stefansson I, et al. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS. 2003;111:1011–8.CrossRefPubMed Salvesen HB, Gulluoglu MG, Stefansson I, et al. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS. 2003;111:1011–8.CrossRefPubMed
31.
Zurück zum Zitat Erdem O, Taskiran C, Onan MA, et al. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol. 2006;103:1007–11.CrossRefPubMed Erdem O, Taskiran C, Onan MA, et al. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol. 2006;103:1007–11.CrossRefPubMed
32.
Zurück zum Zitat Zakrzewski PK, Cygankiewicz AI, Mokrosinski J, et al. Expression of endoglin in primary endometrial cancer. Oncology. 2011;81:243–50.CrossRefPubMed Zakrzewski PK, Cygankiewicz AI, Mokrosinski J, et al. Expression of endoglin in primary endometrial cancer. Oncology. 2011;81:243–50.CrossRefPubMed
33.
Zurück zum Zitat Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524–32.PubMed Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524–32.PubMed
34.
Metadaten
Titel
Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma
verfasst von
Sami K. Saarelainen
Synnöve Staff
Nina Peltonen
Terho Lehtimäki
Jorma Isola
Paula M. Kujala
Maarit H. Vuento
Johanna U. Mäenpää
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1609-6

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.